References
- A'Hern RP, Gore ME (1995). Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol, 13, 726-32.
- Alberts DS, Liu PY, Wilczynski SP et al (2008). Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol, 108, 90-4. https://doi.org/10.1016/j.ygyno.2007.08.075
- Bookman MA, Malmstrom H, Bolis G, et al (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol, 16, 3345-52.
- Chou HH, Wang KL, Chen CA, et al (2006). Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese GynecologicOncology Group study with long-term followup. Gynecol Oncol, 101, 423-8. https://doi.org/10.1016/j.ygyno.2005.10.027
- du Bois A, Pfisterer J, Burchardi N, et al (2007).Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol, 107, 518-25. https://doi.org/10.1016/j.ygyno.2007.08.008
- Fanning J, Bennett TZ, Hilgers RD (1992). Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol, 80, 954-60.
- Ferrandina G, Ludovisi M, Lorusso D, et al (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol, 26, 890-6. https://doi.org/10.1200/JCO.2007.13.6606
- Ferrandina G, Corrado G, Licameli A, et al (2010). Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag, 6, 463-83.
- Ferrero JM, Weber B, Geay JF, et al (2007). Second-line chemotherapy with pegylated Liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol, 18, 263-8.
- Gabizon A, Meshorer A, Barenholz Y (1986). Comparative longterm study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst, 77, 459-69.
- Gabizon A, Papahadjopoulos D (1988). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA, 85, 6949-53. https://doi.org/10.1073/pnas.85.18.6949
- Gabizon A, Catane R, Uziely B, et al (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res, 54, 987-92.
- Gabizon A, Uziely B, Lotem M, et al (1997). Doxil in patients with pretreated metastatic breast cancer (MBC): a doseschedule finding study with pharmacokinetics. Proc Am Soc Clin Oncol, 16, 516.
- Gokhale PC, Radhakrishnan B, Husain SR, et al (1996). An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br J Cancer, 74, 43-8. https://doi.org/10.1038/bjc.1996.313
- Gordon AN, Granai CO, Rose PG, et al (2000). Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol, 18, 3093-100.
- Gordon AN, Fleagle JT, Guthrie D, et al (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol, 19, 3312-22.
- Gordon AN, Tonda M, Sun S, Rackoff W (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol, 95, 1-8. https://doi.org/10.1016/j.ygyno.2004.07.011
- Grover S, Hill-Kayser CE, Vachani C, et al (2012). Patient reported late effects of gynecological cancer treatment. Gynecol Oncol, 124, 399-403. https://doi.org/10.1016/j.ygyno.2011.11.034
- Harashima H, Midori Y, Ohshima S, et al (1993). Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Biopharm Drug Dispos, 14, 595-608. https://doi.org/10.1002/bdd.2510140706
- Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS (1983). Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res, 43, 5427-32.
- Hong RL, Tseng YL (2001). Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer, 91, 1826-33. https://doi.org/10.1002/1097-0142(20010501)91:9<1826::AID-CNCR1203>3.0.CO;2-J
- Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D (1992). Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res, 52, 5135-43.
- Markman M, Hoskins W (1992). Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol, 10, 513-4.
- Markman M, Kennedy A, Webster K, et al (2000). Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxelrefractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Onco, 78, 369-72. https://doi.org/10.1006/gyno.2000.5921
- McGuire WP, Hoskins WJ, Brady MF, et al (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med, 334, 1-6. https://doi.org/10.1056/NEJM199601043340101
- Muggia FM, Hainsworth JD, Jeffers S, et al (1997). Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol, 15, 987-93.
- Papahadjopoulos D, Allen TM, Gabizon A, et al (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA, 88, 11460-4. https://doi.org/10.1073/pnas.88.24.11460
- Power P, Stuart G, Oza A, et al (2009). Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol, 114, 410-4. https://doi.org/10.1016/j.ygyno.2009.04.037
- Rahman A, Treat J, Roh JK, et al (1990). A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol, 8, 1093-100.
- Rose PG, Fusco N, Fluellen L, Rodriguez M (1998). Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol, 16, 1494-7.
- Safra T, Groshen S, Jeffers S, et al (2001). Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer, 91, 90-100. https://doi.org/10.1002/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A
- Shapiro JD, Millward MJ, Rischin D, et al (1996). Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol, 63, 89-93. https://doi.org/10.1006/gyno.1996.0284
- Singal PK, Iliskovic N (1998). Doxorubicin-induced cardiomyopathy. N Engl J Med, 339, 900-5. https://doi.org/10.1056/NEJM199809243391307
- Steffensen KD, Waldstom M, Pallisgard N, et al (2013). Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with kras wildtype the palido study, a phase II nonrandomized multicenter study. Int J Gynecol Cancer, 23, 73-80. https://doi.org/10.1097/IGC.0b013e3182775fae
- Strother R, Matei D (2009). Pegylated liposomal doxorubicin in ovarian cancer. Ther Clin Risk Manag, 5, 639-50.
- Stuart GC, Kitchener H, Bacon M, et al (2011). Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer, 21, 750-5. https://doi.org/10.1097/IGC.0b013e31821b2568
- Williams CJ, Stewart L, Parmar M, Guthrie D (1992). Metaanalysis of the role of platinum compounds in advanced ovarian carcinoma. The advanced ovarian cancer trialists group. Semin Oncol, 19, 120-8.
- Yuda T, Maruyama K, Iwatsuru M (1996). Prolongation of liposome circulation time by various derivatives of polyethyleneglycols. Biol Pharm Bull, 19, 1347-51. https://doi.org/10.1248/bpb.19.1347
Cited by
- Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5215
- Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7277
- Isomeric Folate-Conjugated Polymeric Micelles Bind to Folate Receptors and Display Anticancer Effects vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7363
- Outcomes with Single Agent LIPO-DOX in Platinum-Resistant Ovarian and Fallopian Tube Cancers and Primary Peritoneal Adenocarcinoma - Chiang Mai University Hospital Experience vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1145
- Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box vol.20, pp.9, 2015, https://doi.org/10.3390/molecules200916852
- Nanomedicines for renal disease: current status and future applications vol.12, pp.12, 2016, https://doi.org/10.1038/nrneph.2016.156
- Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment vol.22, pp.4, 2016, https://doi.org/10.1177/1078155215594415